|
π
|
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
7 auth.
B. Cheson,
R. Fisher,
S. Barrington,
F. Cavalli,
L. Schwartz,
E. Zucca,
...
T. Lister
|
11 |
2014 |
11
π
|
|
π
|
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
28 auth.
R. Boellaard,
R. Delgado-Bolton,
W. Oyen,
F. Giammarile,
K. Tatsch,
W. Eschner,
F. Verzijlbergen,
S. Barrington,
L. Pike,
W. Weber,
S. Stroobants,
D. Delbeke,
K. Donohoe,
Scott Holbrook,
M. Graham,
...
G. Testanera,
O. Hoekstra,
J. Zijlstra,
Eric J. W. Visser,
C. Hoekstra,
J. Pruim,
A. Willemsen,
B. Arends,
J. Kotzerke,
A. Bockisch,
T. Beyer,
A. Chiti,
B. Krause
|
11 |
2014 |
11
π
|
|
π’
|
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
21 auth.
P. Johnson,
M. Federico,
A. Kirkwood,
A. FossΓ₯,
L. Berkahn,
A. Carella,
F. d'Amore,
G. Enblad,
A. Franceschetto,
M. Fulham,
...
S. Luminari,
M. O'Doherty,
P. Patrick,
T. Roberts,
G. Sidra,
L. Stevens,
Paul D. Smith,
J. Trotman,
Z. Viney,
J. Radford,
S. Barrington
|
9 |
2016 |
9
π’
|
|
π’
|
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
17 auth.
J. Radford,
T. Illidge,
N. Counsell,
B. Hancock,
R. Pettengell,
P. Johnson,
J. Wimperis,
D. Culligan,
B. Popova,
Paul Smith,
...
A. McMillan,
A. Brownell,
A. Kruger,
A. Lister,
P. Hoskin,
M. O'Doherty,
S. Barrington
|
9 |
2015 |
9
π’
|
|
π
|
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
9 auth.
B. Cheson,
S. Ansell,
L. Schwartz,
L. Gordon,
R. Advani,
H. Jacene,
...
A. Hoos,
S. Barrington,
P. Armand
|
8 |
2016 |
8
π
|
|
π¦
|
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
15 auth.
S. Barrington,
W. Qian,
E. Somer,
A. Franceschetto,
B. Bagni,
E. Brun,
H. Almquist,
A. Loft,
L. HΓΈjgaard,
M. Federico,
...
A. Gallamini,
Paul Smith,
P. Johnson,
J. Radford,
M. O'Doherty
|
8 |
2010 |
8
π¦
|
|
π’
|
International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers
10 auth.
A. Biggi,
A. Gallamini,
S. Chauvie,
M. Hutchings,
L. Kostakoglu,
M. Gregianin,
...
M. Meignan,
B. MaΕkowski,
M. Hofman,
S. Barrington
|
8 |
2013 |
8
π’
|
|
π’
|
Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL
8 auth.
G. Mikhaeel,
Daniel J. Smith,
J. Dunn,
M. Phillips,
H. MΓΈller,
P. Fields,
...
D. Wrench,
S. Barrington
|
7 |
2016 |
7
π’
|
|
π
|
Quantification of absolute myocardial perfusion in patients with coronary artery disease: comparison between cardiovascular magnetic resonance and positron emission tomography.
14 auth.
G. Morton,
A. Chiribiri,
M. Ishida,
Shazia T. Hussain,
A. Schuster,
A. Indermuehle,
D. Perera,
J. Knuuti,
Stacey Baker,
Erik HedstrΓΆm,
...
P. Schleyer,
M. O'Doherty,
S. Barrington,
E. Nagel
|
7 |
2012 |
7
π
|
|
π
|
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
25 auth.
A. Gallamini,
S. Barrington,
A. Biggi,
S. Chauvie,
L. Kostakoglu,
M. Gregianin,
M. Meignan,
G. Mikhaeel,
A. Loft,
J. Zaucha,
J. Seymour,
M. Hofman,
L. Rigacci,
A. Pulsoni,
M. Coleman,
...
E. Dann,
L. Trentin,
O. Casasnovas,
C. Rusconi,
P. Brice,
S. Bolis,
S. Viviani,
F. Salvi,
S. Luminari,
M. Hutchings
|
7 |
2014 |
7
π
|
|
π
|
PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.
7 auth.
A. Khan,
S. Barrington,
N. Mikhaeel,
A. Hunt,
L. Cameron,
Timothy Morris,
...
R. Carr
|
7 |
2013 |
7
π
|
|
π’
|
PET/CT for Therapy Response Assessment in Lymphoma
M. Hutchings,
S. Barrington
|
7 |
2009 |
7
π’
|
|
π¦
|
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
S. Barrington,
R. Kluge
|
7 |
2017 |
7
π¦
|
